Actively Recruiting
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
Led by Fudan University · Updated on 2026-03-03
110
Participants Needed
1
Research Sites
157 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
CONDITIONS
Official Title
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older, male or female
- Histologically or cytologically confirmed locally advanced or metastatic melanoma
- Positive NRAS mutation confirmed by prior genetic testing
- Failed prior anti-PD-1 or anti-PD-L1 therapy
- Able to take oral medications
- Willing to participate voluntarily, sign informed consent, and comply with study requirements
You will not qualify if you...
- Currently participating in other clinical drug trials
- Pregnant or breastfeeding
- Conditions unsuitable for targeted therapy after multidisciplinary discussion
- Other factors deemed inappropriate by the investigator, including familial or social issues that affect safety or data collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
Research Team
Y
Yu Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here